pirfenidonenintedanibmycophenolate mofetiltreprostiniltocilizumab
…ow (see section on Current treatments). The antifibrotic drugs, pirfenidone and nintedanib, are established treatments for idiopathic pulmo…
7articles mentioning drugs
46drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Nerandomilast ×
Nerandomilast
This drug is selected. Its supporting articles are shown below.
Articles mentioning Nerandomilast
7 articles · page 1 of 1nerandomilastmycophenolate mofetilSystemic sclerosis (SSc)idiopathic pulmonary fibrosisprogressive pulmonary fibrosis
… profibrotic or proinflammatory cytokines and then treated with nerandomilast. Investigations included cell proliferation, fibrosis-associate…
nerandomilastnintedanibPrednisonemycophenolaterituximabtocilizumabCyclophosphamideSSc-ILD
…in 4 (17.4%), 7 (28.0%) and 11 (40.7%) patients in the placebo, nerandomilast 9 mg and 18 mg BID groups, respectively. Rates of treatment dis…
NerandomilastBI 1015550pulmonary fibrosisIIM-ILDidiopathic inflammatory myopathies-associated interstitial lung disease (IIM-ILD)
…il extracellular trap formation (NETosis) and EndMT.Conclusions Nerandomilast alleviates IIM-ILD by inhibiting NET formation and suppressing …
pirfenidonenintedanibnerandomilastpulmonary fibrosisUS
…t treatment for pulmonary fibrosis is limited to nintedanib and pirfenidone, which slow but do not halt or reverse the progression of the d…
nerandomilastsystemic glucocorticoidsinterstitial lung disease (ILD)antifibrotic medications
…reated with antifibrotic medication. Emerging therapies include nerandomilast, a phosphodiesterase 4B inhibitor with antifibrotic and immunom…
TreprostinilnerandomilastnintedanibpirfenidoneIdiopathic Pulmonary Fibrosis (IPF)pulmonary hypertension
…and hydroxyproline content levels in the PCLS model.Conclusions Treprostinil inhibits RhoA activation and this may be via PPARβδ activation.…